CEL-SCI Stock Forecast, Price & News

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

What stocks does MarketBeat like better than CEL-SCI?

Wall Street analysts have given CEL-SCI a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CEL-SCI wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Wednesday, December 29th 2021.
View our earnings forecast for CEL-SCI.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) issued its quarterly earnings data on Monday, August, 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.12.
View CEL-SCI's earnings history.

How has CEL-SCI's stock price been impacted by COVID-19?

CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CVM stock has increased by 22.7% and is now trading at $11.95.
View which stocks have been most impacted by COVID-19.

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

Shares of CEL-SCI reverse split before market open on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:

• Geert R. Kersten, CEO, Chief Financial Officer, Treasurer & Director
• Patricia B. Prichep, Secretary & Senior Vice President-Operations
• Eyal Talor, Chief Scientific Officer
• William Jones, Vice President-Quality Assurance
• Daniel H. Zimmerman, Senior VP-Research & Cellular Immunology

Who are some of CEL-SCI's key competitors?

Some companies that are related to CEL-SCI include Alector (ALEC), REGENXBIO (RGNX), Rubius Therapeutics (RUBY), Valneva (VALN), Replimune Group (REPL), AlloVir (ALVR), Immunocore (IMCR), Ocugen (OCGN), Caribou Biosciences (CRBU), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Inhibrx (INBX), Agenus (AGEN), Coherus BioSciences (CHRS) and Vaxcyte (PCVX).
View all of CVM's competitors.

What other stocks do shareholders of CEL-SCI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Savara (SVRA), Molecular Templates (MTEM), Gilead Sciences (GILD), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA), VBI Vaccines (VBIV) and CymaBay Therapeutics (CBAY).

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.58%), State Street Corp (6.55%), Vanguard Group Inc. (4.84%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Bank of America Corp DE (0.00%). Company insiders that own CEL-SCI stock include Geert R Kersten, John Cipriano, Patricia B Prichep, Peter R Young and Robert Eugene Watson.
View institutional ownership trends for CEL-SCI.

Which major investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including Mangrove Partners, Citadel Advisors LLC, Walleye Trading LLC, Commonwealth Equity Services LLC, Western Standard LLC, Susquehanna International Group LLP, Goldman Sachs Group Inc., and Rafferty Asset Management LLC.
View insider buying and selling activity for CEL-SCI or view top insider-selling stocks.

Which major investors are buying CEL-SCI stock?

CVM stock was bought by a variety of institutional investors in the last quarter, including Group One Trading L.P., BlackRock Inc., Simplex Trading LLC, Vanguard Group Inc., Cutler Group LP, JPMorgan Chase & Co., Natixis, and Schonfeld Strategic Advisors LLC. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Patricia B Prichep, Peter R Young, and Robert Eugene Watson.
View insider buying and selling activity for CEL-SCI or or view top insider-buying stocks.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $11.95.

How much money does CEL-SCI make?

CEL-SCI has a market capitalization of $514.18 million and generates $560,000.00 in revenue each year. The company earns $-30,250,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does CEL-SCI have?

CEL-SCI employs 2,020 workers across the globe.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

Where are CEL-SCI's headquarters?

CEL-SCI is headquartered at 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at (703) 506-9460 or via email at [email protected].